TRPC6 Characterization to Predict and Prevent Chemotherapy Related Cardiomyopathy and Heart Failure With Breast Cancer

Who May Qualify: - 18 years of age or older - Any breast cancer patient initiating doxorubicin/other anthracycline and patients receiving trastuzumab without doxorubicin/anthracycline in the neoadjuvant/adjuvant setting - An understanding of the protocol and its requirements, risks, and discomforts - The ability and willingness to sign an willing to sign a consent form - Diagnosed with therapy related cardiotoxicity defined as; cardiomyopathy, symptomatic heart failure, asymptomatic reduced systolic function, acute coronary syndrome, myocardial infarction, critical limb ischemia, cardiac arrhythmias or myocarditis possibly related to prior cancer treatment OR completed chemotherapy with no cardiotoxicity at least two years post treatment OR patients with cancer who will be initiating systemic therapy with potentially cardiotoxic medications. This will include doxorubicin chemotherapy, or trastuzumab. - Healthy, non-pregnant, adult subjects who weigh at least 110 pounds Who Should NOT Join This Trial: - Inability on the part of the patient to understand the willing to sign a consent form or be compliant with the protocol - Anemia with hemoglobin less than 8 - Patients not willing to undergo a blood draw - Patients with stage IV or distant metastatic breast cancer Always talk to your doctor about whether this trial is right for you.